Apart from targeting the neuronal BDNF pathway, entrectinib gains importance in therapy and diagnostics of CNS tumors: The 2021 WHO classification identifies a new class of infant-type hemispheric glioma presenting with receptor tyrosine kinase fusions with ALK, ROS1, NTRK1/2/3, or MET [1]. This evidence concerns the gene NTRK1 and glioma.